A comprehensive review of an unmet public health issue: resistant hypertension

References

• Weiwei Chen, Runlin Gao, Lisheng Liu. China cardiovascular report of 2014. China Circ J 2015;(7):617–622
   Google Scholar
• Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003;289(18):2363–2369.
   PubMed Web of Science ®Google Scholar
• Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999–2004. Hypertension 2007;49(1):69–75.
   PubMed Web of Science ®Google Scholar
• Ma W, Zhang Y. Low rate of resistant hypertension in Chinese patients with hypertension: an analysis of the HOT-CHINA study. J Hypertens 2013;31(12):2386–2390.
   PubMed Web of Science ®Google Scholar
• Perkovic V, Huxley R, Wu Y, et al. The burden of blood pressure-related disease: a neglected priority for global health. Hypertension 2007;50(6):991–997.
   PubMed Web of Science ®Google Scholar
• Ningling Sun. Consensus of resistant hypertension of China hypertension committee. China Circ J 2014;(4):241–243.
   Google Scholar
• Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013;31(7):1281–357.
   Google Scholar
• Ben-Dov I, Grossman E, Stein A, et al. Marked weight reduction lowers resting and exercise blood pressure in morbidly obese subjects. Am J Hypertens 2000;13(3):251–255.
   PubMed Web of Science ®Google Scholar
• John JH, Ziebland S, Yudkin P, et al. Effects of fruit and vegetable consumption on plasma antioxidant concentrations and blood pressure: a randomised controlled trial. Lancet 2002;359(9322):1969–1974.
   PubMed Web of Science ®Google Scholar
• Meland E, Aamland A. Salt restriction among hypertensive patients: modest blood pressure effect and no adverse effects. Scand J Prim Health Care 2009;27(2):97–103.
   PubMed Web of Science ®Google Scholar
• Li G, Cai AP, Mo YJ, et al. Effects of guideline-based hypertension management in rural areas of Guangdong Province. Chin Med J (Engl) 2015;128(6):799–803.
   PubMed Web of Science ®Google Scholar
• Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension2003;42(6):1206–1252.
   PubMed Web of Science ®Google Scholar
• Persell SD. Prevalence of resistant hypertension in the United States, 2003–2008. Hypertension 2011;57(6):1076–1080.
   PubMed Web of Science ®Google Scholar
• Egan BM, Zhao Y, Axon RN, et al. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 2011;124(9):1046–1058.
   PubMed Web of Science ®Google Scholar
• de la Sierra A, Segura J, Banegas JR, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension 2011;57(5):898–902.
   PubMed Web of Science ®Google Scholar
• Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Circulation 2008;117(25):e510–e526.
   PubMed Web of Science ®Google Scholar
• Egan BM, Zhao Y, Li J, et al. Prevalence of optimal treatment regimens in patients with apparent treatment-resistant hypertension based on office blood pressure in a community-based practice network. Hypertension 2013;62(4):691–697.
   PubMed Web of Science ®Google Scholar
• Egan BM, Zhao Y, Axon RN, et al. Uncontrolled and apparent treatment resistant hypertension in the United States, 1988 to 2008. Circulation 2011;124(9):1046–1058.
   PubMed Web of Science ®Google Scholar
• Muntner P, Davis BR, Cushman WC, et al. Treatment-resistant hypertension and the incidence of cardiovascular disease and end-stage renal disease: results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 2014;64(5):1012–1021.
   PubMed Web of Science ®Google Scholar
• Acelajado MC, Pisoni R, Dudenbostel T, et al. Refractory hypertension: definition, prevalence, and patient characteristics. J Clin Hypertens (Greenwich) 2012;14(1):7–12.
   PubMed Web of Science ®Google Scholar
• Kikuya M, Hansen TW, Thijs L, et al, On behalf of the IDACO investigators. Diagnostic thresholds for ambulatory blood pressure monitoring based on 10-Year cardiovascular risk Circulation2007;115:2145–2152.
   Google Scholar
• Parati G, Stergiou G, O’Brien E, et al. European Society of Hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens 2014;32(7):1359–66.
   PubMed Web of Science ®Google Scholar
• Stranges PM, Drew AM, Rafferty P, et al. Treatment of hypertension with chronotherapy: is it time of drug administration. Ann Pharmacother 2015;49(3):323–334.
   PubMed Web of Science ®Google Scholar
• Burnier M, Wuerzner G, Struijker-Boudier H, Urquhart J. Measuring, analyzing, and managing drug adherence in resistant hypertension. Hypertension 2013;62(2):218–225.
   PubMed Web of Science ®Google Scholar
• Burnier M, Schneider MP, Chiolero A, et al. Electronic compliance monitoring in resistant hypertension: the basis for rational therapeutic decisions. J Hypertens 2001;19(2):335–341.
   PubMed Web of Science ®Google Scholar
• Daugherty SL, Powers JD, Magid DJ, et al. The association between medication adherence and treatment intensification with blood pressure control in resistant hypertension. Hypertension 2012;60(2):303–309.
   PubMed Web of Science ®Google Scholar
• Hanselin MR, Saseen JJ, Allen RR, et al. Description of antihypertensive use in patients with resistant hypertension prescribed four or more agents. Hypertension 2011;58(6):1008–1013.
   PubMed Web of Science ®Google Scholar
• Rimoldi SF, Messerli FH, Bangalore S, Scherrer U. Resistant hypertension: what the cardiologist needs to know. Eur Heart J 2015;36(40):2686–2695.
   PubMed Web of Science ®Google Scholar
• Chandran P. Resistant or difficult-to-control hypertension. N Engl J Med 2006;355(18):1934; author reply 1934.
   PubMed Web of Science ®Google Scholar
• Muxfeldt ES, Salles GF. Pulse pressure or dipping pattern: which one is a better cardiovascular risk marker in resistant hypertension. J Hypertens 2008;26(5): 878–884.
   PubMed Web of Science ®Google Scholar
• Ferrari P. Reasons for therapeutic inertia when managing hypertension in clinical practice in non-Western countries. J Hum Hypertens 2009;23(3):151–159.
   PubMed Web of Science ®Google Scholar
• Oliveria SA, Lapuerta P, McCarthy BD, et al. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med 2002;162(4):413–420.
   PubMedGoogle Scholar
• Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen. Eur Heart J 2014;35(19):1245–1254.
   PubMed Web of Science ®Google Scholar
• Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012;125(13):1635–1642.
   PubMed Web of Science ®Google Scholar
• Williams B, MacDonald TM, Morant S, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial.LID – S0140-6736(15)00257-3 [pii]LID – 10.1016/S0140-6736(15)00257-3 [doi]. Lancet 2015.
   Google Scholar
• Dietz JD, Du S, Bolten CW, et al. A number of marketed dihydropyridine calcium channel blockers have mineralocorticoid receptor antagonist activity. Hypertension 2008;51(3):742–748.
   PubMed Web of Science ®Google Scholar
• Lea WB, Kwak ES, Luther JM, et al. Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt. Kidney Int 2009;75(9):936–944.
   PubMed Web of Science ®Google Scholar
• Schumacher CD, Steele RE, Brunner HR. Aldosterone synthase inhibition for the treatment of hypertension and the derived mechanistic requirements for a new therapeutic strategy. J Hypertens 2013;31(10):2085–2093.
   PubMed Web of Science ®Google Scholar
• Fraga-Silva RA, Ferreira AJ, Dos SRA. Opportunities for targeting the angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor pathway in hypertension. Curr Hypertens Rep 2013;15(1):31–38.
   PubMed Web of Science ®Google Scholar
• Ferreira AJ, Murca TM, Fraga-Silva RA, et al. New cardiovascular and pulmonary therapeutic strategies based on the angiotensin-converting enzyme 2/angiotensin-(1-7)/mas receptor axis. Int J Hypertens 2012;2012:147825.
   PubMedGoogle Scholar
• Ruilope LM, Dukat A, Bohm M, et al. Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study. Lancet 2010;375(9722):1255–1266.
   PubMed Web of Science ®Google Scholar
• Kario K, Sun N, Chiang FT, et al. Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study. Hypertension 2014;63(4):698–705.
   PubMed Web of Science ®Google Scholar
• Oparil S, Schmieder RE. New approaches in the treatment of hypertension. Circ Res 2015;116(6):1074–1095.
   PubMed Web of Science ®Google Scholar
• DiBona GF, Kopp UC. Neural control of renal function. Physiol Rev 1997;77(1):75–197.
   PubMed Web of Science ®Google Scholar
• Krum H, Schlaich M, Whitbourn R, et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009;373(9671):1275–1281.
   PubMed Web of Science ®Google Scholar
• Esler MD, Krum H, Sobotka PA, et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010;376(9756):1903–1909.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Kandzari DE, O’Neill WW, et al. A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014;370(15):1393–1401.
   PubMed Web of Science ®Google Scholar
• Heusser K, Tank J, Engeli S, et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension 2010;55(3):619–626.
   PubMed Web of Science ®Google Scholar
• Scheffers IJ, Kroon AA, Schmidli J, et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol 2010;56(15):1254–1258.
   PubMed Web of Science ®Google Scholar
• Hoppe UC, Brandt MC, Wachter R, et al. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens 2012;6(4):270–276.
   PubMed Web of Science ®Google Scholar